<DOC>
	<DOCNO>NCT00006968</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy donor peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I/II trial study effectiveness pentostatin follow peripheral stem cell transplantation treat patient advanced kidney cancer .</brief_summary>
	<brief_title>Pentostatin Followed Peripheral Stem Cell Transplantation Treating Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine duration efficiency hematopoietic immunologic engraftment patient advance renal cell carcinoma treat pentostatin follow related allogeneic stem cell transplantation . - Determine hematologic non-hematologic toxic effect regimen patient . - Determine incidence severity graft-versus-host disease patient treat regimen . OUTLINE : This dose-escalation study pentostatin . - Phase I : Patients receive pentostatin IV day -7 , -5 , -3 follow allogeneic stem cell transplantation day 0 . Beginning day 1 , patient receive filgrastim ( G-CSF ) IV 1 hour subcutaneously daily blood count recover . As graft-versus-host disease prophylaxis , patient receive cyclosporine IV continuously stem cell engraftment orally gradual tapering . Cohorts 3 6 patient receive escalate dos pentostatin maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive treatment phase I MTD pentostatin . Patients follow weekly 60 day monthly 10 month . PROJECTED ACCRUAL : A total 24 patient ( 12 per phase ) accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced renal cell cancer No bone metastases No CNS disease Must allogeneic donor available PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 01 Life expectancy : 3 6 month Hematopoietic : Hemoglobin least 10 g/dL Complete blood count normal Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) Transaminases great 4 time ULN No evidence portal hypertension Renal : Creatinine great 2.0 mg/dL No uncontrolled hypercalcemia Cardiovascular : No New York Heart Association class 3 4 heart disease Pulmonary : DLCO least 40 % predict Other : No severe functional neurological impairment HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior biologic therapy Chemotherapy : No 6 month prior chemotherapy Endocrine therapy : At least 1 year since prior steroid Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>